TSC2 and neoplasm: We next assessed the possible benefit of the ASAH1 inhibitor 17a in a xenograft tumor model in which Tsc2-null ELT3 luciferase-expressing cells were implanted subcutaneously into immunodeficient NOD/SCID-γ–null (NSG) mice (25).